• YouTube

 

2017:

  • Ambrosioni J, Coiras M, Alcamí J, Miró JM. Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Expert Rev Anti Infect Ther. 2017 Mar 21. [Epub ahead of print]
  • Calonge E, Bermejo M, Diez-Fuertes F, Mangeot I, Gonzalez N, Coiras M, et al. Different Expression of Interferon Stimulated Genes in Response to HIV-1 Infection in Dendritic Cells According to Their Maturation State. J Virol. 2017 Feb 1. [Epub ahead of print]
  • Olmedo DA, López-Pérez JL, Del Olmo E, Bedoya LM, Sancho R, Alcamí J, et al. Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-κB Pathways. Molecules. 2017 Feb 19;22(2).
  • Saba E, Panina-Bordignon P, Pagani I, Origoni M, Candiani M, Doglioni C, et al. 5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. Antiviral Res. 2017 Mar 7;142:16-20. [Epub ahead of print]
  • Vanwalscappel B, Rato S, Perez-Olmeda M, Díez Fuertes F, Casartelli N, Alcami J, et al. Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients. Virology. 2017 Jan;500:247-258.

2016:

  • Bedoya LM, Beltrán M, Obregón-Calderón P, García-Pérez J, de la Torre HE, González N, et al. Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity. AIDS. 2016 Nov 28;30(18):2767-2776.
  • Benureau Y, Colin P, Staropoli I, Gonzalez N, Garcia-Perez J, Alcami J, et al. Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins. J Virol Methods. 2016 Jul 20;236:184-195.
  • Bermejo M, López-Huertas MR, García-Pérez J, Climent N, Descours B, Ambrosioni J, et al. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochem Pharmacol. 2016 Apr 15;106:30-45.
  • Coiras M, Bermejo M, Descours B, Mateos E, García-Pérez J, López-Huertas MR, et al. IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. Cell Rep. 2016 Mar 8;14(9):2100-7.
  • Dominguez-Molina B, Leon A, Rodriguez C, Benito JM, Lopez-Galindez C, Garcia F, Del Romero J, Gutierrez F, Viciana P, Alcami J, Leal M, Ruiz-Mateos E; Spanish AIDS Research Network HIV Controllers Cohort (ECRIS). Analysis of Non-AIDS-Defining Events in HIV Controllers. Clin Infect Dis. 2016 May 15;62(10):1304-9.
  • Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, Vidal F, Tural C, Moreno S, Goñi JM, Ramírez de Arellano E, Del Val M, Gonzalez-Escribano MF, Del Romero J, Rodriguez C, Capa L, Viciana P, Alcamí J, Yu XG, Walker BD, M L, Lichterfeld M, Ruiz-Mateos E; ECRIS integrated in the Spanish AIDS Research Network. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clin Infect Dis. 2016 Dec 16. pii: ciw833. [Epub ahead of print]
  • Herrera C, Armanasco N, García-Pérez J, Ziprin P, Olejniczak N, Alcamí J, et al. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. AIDS. 2016 Apr 24;30(7):1015-25.
  • Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C, Rallon N, Alcami J, Lopez-Aldeguer J, Viciana P, Rodriguez C, Grau E, Iribarren J, Gatell JM, Garcia F; EC and Immune Pathogenesis Working group of the Spanish AIDS Research Network. Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS. 2016 May 15;30(8):1209-20.
  • López-Huertas MR, Li J, Zafar A, Rodríguez-Mora S, García-Domínguez C, Mateos E, et al. PKCθ and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4(+) T Cells. Front Immunol. 2016 Feb 29;7:69.
  • Martín V, Perales C, Fernández-Algar M, Dos Santos HG, Garrido P, Pernas M, et al. An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. PLoS One. 2016 Dec 13;11(12):e0166902.
  • Prado S, Beltrán M, Coiras M, Bedoya LM, Alcamí J, Gallego J. Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen. Biochem Pharmacol. 2016 May 1;107:14-28.
  • Rallón N, Mothe B, Lopez Bernaldo de Quiros JC, Plana M, Ligos JM, Montoya M, Muñoz-Fernández MA, Esteban M, Garcia F, Brander C, Benito JM; RISVAC03 Study Group. Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. AIDS. 2016 Feb 20;30(4):553-62.
  • Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, et al. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. J Virol. 2016 May 12;90(11):5231-45.

2015:

  • Bermejo M, López-Huertas MR, Hedgpeth J, Mateos E, Rodríguez-Mora S, Maleno MJ, et al. Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. Biochem Pharmacol. 2015 Apr 15;94(4):241-56.
  • Callies O, Bedoya LM, Beltrán M, Muñoz A, Calderón PO, Osorio AA, et al. Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. J Nat Prod. 2015 May 22;78(5):1045-55.
  • Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, et al. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology. 2015 Jun 18;12:50.
  • Gianvincenzo PD, Calvo J, Perez S, Álvarez A, Bedoya LM, Alcamí J, et al. Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: toward fully synthetic HIV vaccine candidates. Bioconjug Chem. 2015 Apr 15;26(4):755-65.
  • Montes M, Coiras M, Becerra S, Moreno-Castro C, Mateos E, Majuelos J, et al. Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing. PLoS One. 2015 Oct 13;10(10):e0139812.
  • Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. J Antimicrob Chemother. 2015 Jun;70(6):1833-42.
  • Rodríguez-Mora S, Mateos E, Moran M, Martín MÁ, López JA, Calvo E, et al. Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication. Retrovirology. 2015 Sep 16;12(1):78.
  • Thomas A, Mariani-Floderer C, López-Huertas MR, Gros N, Hamard-Péron E, Favard C, et al. Involvement of the Rac1-IRSp53-Wave2-Arp2/3 Signaling Pathway in HIV-1 Gag Particle Release in CD4 T Cells. J Virol. 2015 Aug;89(16):8162-81.

2014:

  • Vidal F, Leal M, Alcamí J, Domingo P. Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Pharmacogenomics. 2014 Apr;15(5):569-72.

2013:

  • Anta L, Blanco JL, Llibre JM, García F, Pérez-Elías MJ, Aguilera A, Pérez-Romero P, Caballero E, Vidal C, Cañizares A, Gutiérrez F, Dalmau D, Iribarren JA, Soriano V, de Mendoza C; Drug Resistance Platform of the Spanish AIDS Research Network. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. J Antimicrob Chemother. 2013 Sep;68(9):1994-2002.
  • Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C; Resistance Platform of the Spanish AIDS Research Network. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS. 2013 Jan 2;27(1):81-5.
  • Coiras M, Montes M, Montanuy I, López-Huertas MR, Mateos E, Le Sommer C, et al. Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication. Retrovirology. 2013 Oct 28;10(1):124.
  • Colin P, Bénureau Y, Staropoli I, Wang Y, Gonzalez N, Alcami J, et al. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9475-80.
  • González-Bulnes L, Ibáñez I, Bedoya LM, Beltrán M, Catalán S, Alcamí J, et al. Structure-based design of an RNA-binding p-terphenylene scaffold that inhibits HIV-1 Rev protein function. Angew Chem Int Ed Engl. 2013 Dec 9;52(50):13405-9.
  • Guardo AC, Alvarez-Fernández C, Arberas H, García-Pérez J, García F, Bargalló ME, et al. Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals. PLoS One. 2013;8(3):e58927.
  • López-Huertas MR, Mateos E, Sánchez Del Cojo M, Gómez-Esquer F, Díaz-Gil G, Rodríguez-Mora S, et al. The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem. 2013 Mar 15;288(11):7626-44.
  • Machmach K, Abad-Molina C, Romero-Sánchez MC, Abad MA, Ferrando-Martínez S, Genebat M, Pulido I, Viciana P, González-Escribano MF, Leal M, Ruiz-Mateos E; HIV Controllers Consortium of the AIDS Spanish Network. IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. J Infect Dis. 2013 Feb 15;207(4):651-5.
  • Pérez-Olmeda M, Alcami J. Determination of HIV tropism and its use in the clinical practice. Expert Rev Anti Infect Ther. 2013 Dec;11(12):1291-302.
  • Sanjuán R, Nebot MR, Peris JB, Alcamí J. Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1. PLoS Biol. 2013;11(4):e1001523.

2012:

  • Álvarez-Fernández C, Crespo Guardo A, García-Pérez J, García F, Blanco J, Escribà-García L, et al. Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. PLoS One. 2012;7(11):e48848.
  • Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elías MJ, de Mendoza C, Martínez MA, Martinez-Picado J, Menéndez-Arias L; Resistance Platform of the Spanish AIDS Research Network (ResRIS), Iribarren JA, Caballero E, Ribera E, Llibre JM, Clotet B, Jaén A, Dalmau D, Gatel JM, Peraire J, Vidal F, Vidal C, Riera M, Córdoba J, López Aldeguer J, Galindo MJ, Gutiérrez F, Álvarez M, García F, Pérez-Romero P, Viciana P, Leal M, Palomares JC, Pineda JA, Viciana I, Santos J, Rodríguez P, Gómez Sirvent JL, Gutiérrez C, Moreno S, Pérez-Olmeda M, Alcamí J, Rodríguez C, del Romero J, Cañizares A, Pedreira J, Miralles C, Ocampo A, Morano L, Aguilera A, Garrido C, Manuzza G, Poveda E, Soriano V. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology. 2012 Aug 13;9:68.
  • Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, et al. International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One. 2012;7(5):e36438.
  • Messiaen P, De Spiegelaere W, Alcami J, Vervisch K, Van Acker P, Verhasselt B, et al. Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression. PLoS One. 2012;7(11):e50204.
  • Olmedo D, Sancho R, Bedoya LM, López-Pérez JL, Del Olmo E, Muñoz E, et al. 3-Phenylcoumarins as inhibitors of HIV-1 replication. Molecules. 2012 Aug 2;17(8):9245-57.
  • Osorio AA, Muñóz A, Torres-Romero D, Bedoya LM, Perestelo NR, Jiménez IA, et al. Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription. Eur J Med Chem. 2012 Jun;52:295-303.
  • Peña J, Frías M, Castro-Orgaz L, González R, García F, Gallart T, Gatell JM, Plana M; Dc2-Manon07 Vaccine Research Group. Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection. Viral Immunol. 2012 Feb;25(1):37-44.
  • Poveda E, Paredes R, Moreno S, Alcamí J, Córdoba J, Delgado R, et al. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Rev. 2012 Jul-Sep;14(3):208-17. Review.

2011:

  • Alcamí J, Coiras M. Inmunopatogenia de la infección por el virus de la inmunodeficiencia humana [Immunopathogenesis of HIV infection]. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):216-26. Review. Spanish.
  • García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011 Oct 26;29(46):8309-16.
  • García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, Martínez-Picado J, Lifson J, Autran B, Costagliola D, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07- AIDS Vaccine Research Objective Study Group. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011 Feb 15;203(4):473-8.
  • Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B, et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem. 2011 Sep 23;286(38):33409-21.
  • Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F, et al. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem. 2011 Feb 18;286(7):4978-90.
  • López-Huertas MR, Mateos E, Díaz-Gil G, Gómez-Esquer F, Sánchez del Cojo M, Alcamí J, et al. Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes. J Biol Chem. 2011 Aug 5;286(31):27363-77.
  • Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol. 2011 Jun;85(12):5804-13.
  • Pineda JA, Alcami J, Blanco JR, Blanco J, Boix V, Casado JL, et al. Temas de actualidad sobre inmunologia en la infeccion por el VIH. J AIDS Clinic Res. 2011 Feb;2(2).
  • Sánchez-Del Cojo M, López-Huertas MR, Mateos E, Alcamí J, Coiras M. Mechanisms of RNA interference in the HIV-1-host cell interplay. AIDS Rev. 2011 Jul-Sep;13(3):149-60. Review.
  • Sánchez-Palomino S, Massanella M, Carrillo J, García A, García F, González N, et al. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine. 2011 Jul 18;29(32):5250-9.
  • Santiago B, Calonge E, Del Rey MJ, Gutierrez-Cañas I, Izquierdo E, Usategui A, et al. CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. Cytokine. 2011 Feb;53(2):184-90.
  • Vidal F, Domingo P, Viladés C, Peraire J, Arnedo M, Alcamí J, et al. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1365-82.

2010:

  • Bedoya LM, Abad MJ, Calonge E, Saavedra LA, Gutierrez C M, Kouznetsov VV, et al. Quinoline-based compounds as modulators of HIV transcription through NF-kappaB and Sp1 inhibition. Antiviral Res. 2010 Sep;87(3):338-44.
  • Bedoya LM, Abad MJ, Sánchez-Palomino S, Alcami J, Bermejo P. Ellagitannins from Tuberaria lignosa as entry inhibitors of HIV. Phytomedicine. 2010 Jan;17(1):69-74.
  • Calonge E, Alonso-Lobo JM, Escandón C, González N, Bermejo M, Santiago B, et al. c/EBPbeta is a major regulatory element driving transcriptional activation of the CXCL12 promoter. J Mol Biol. 2010 Feb 26;396(3):463-72.
  • Coiras M, Lopez-Huertas MR, Alcami J. Latencia de VIH y erradicación. AIDS Cyber J 2010 Nov.
  • Coiras M, Lopez-Huertas MR, Alcami J. HIV-1 latency and eradication of long-term viral reservoirs. Discov Med. 2010 Mar;9(46):185-91. Review.
  • Coiras M, López-Huertas MR, Sánchez del Cojo M, Mateos E, Alcamí J. Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle. AIDS Rev. 2010 Apr-Jun;12(2):103-12. Review.
  • Coiras M, López-Huertas MR, Sánchez del Cojo M, Mateos E, Alcamí J. HIV Latency – Treatment of Viral Infection and Prospects for the Eradication of Latent Reservoirs. Eur Infect Dis, 2010;4(2):10-6.
  • De Arellano ER, Alcamí J, López M, Soriano V, Holguín A. Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. Antiviral Res. 2010 Nov;88(2):152-9.
  • Di Gianvincenzo P, Marradi M, Martínez-Avila OM, Bedoya LM, Alcamí J, Penadés S. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg Med Chem Lett. 2010 May 1;20(9):2718-21.
  • González N, Alvarez A, Alcamí J. Broadly neutralizing antibodies and their significance for HIV-1 vaccines. Curr HIV Res. 2010 Dec;8(8):602-12. Review.
  • González N, Bermejo M, Calonge E, Jolly C, Arenzana-Seisdedos F, Pablos JL, et al. SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse. J Virol. 2010 May;84(9):4341-51.
  • González N, Pérez-Olmeda M, Mateos E, Cascajero A, Alvarez A, Spijkers S, et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother. 2010 Dec;65(12):2493-501.
  • López-Huertas MR, Callejas S, Abia D, Mateos E, Dopazo A, Alcamí J, et al. Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res. 2010 Jun;38(10):3287-307.
  • Poveda E, Alcamí J, Paredes R, Córdoba J, Gutiérrez F, Llibre JM, et al. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 2010 Jul-Sep;12(3):135-48. Review.

2009:

  • Alvaro-Blanco J, Martínez-Gac L, Calonge E, Rodríguez-Martínez M, Molina-Privado I, Redondo JM, et al. A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence. Carcinogenesis. 2009 Mar;30(3):440-8.
  • Bedoya LM, Márquez N, Martínez N, Gutiérrez-Eisman S, Alvarez A, Calzado MA, et al. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochem Pharmacol. 2009 Mar 15;77(6):965-78.
  • Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009 Nov;7(11):798-812.
  • De Mendoza C, Anta L, García F, Pérez-Elías MJ, Gutiérrez F, Llibre JM, et al. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. AIDS Rev. 2009 Jan-Mar;11(1):39-51.
  • Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One. 2009;4(2):e4505.
  • García-Merino I, de Las Cuevas N, Jiménez JL, Gallego J, Gómez C, Prieto C, Serramía MJ, Lorente R, Muñoz-Fernández MA; Spanish HIV BioBank. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology. 2009 Mar 9;6:27.
  • Garcia-Moruja C, Rueda P, Torres C, Alcamí J, Luque F, Caruz A. Molecular phenotype of CXCL12beta 3'UTR G801A polymorphism (rs1801157) associated to HIV-1 disease progression. Curr HIV Res. 2009 Jul;7(4):384-9.
  • Martínez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcamí J, Penadés S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. Chembiochem. 2009 Jul 20;10(11):1806-9.
  • Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, et al. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol. 2009 Feb;81(2):211-6.

2008:

  • Alcamí J. Maraviroc. Introducción. Una breve historia del sida [Introduction. A brief history of AIDS]. Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:1-4. Spanish.
  • Alcamí J. Maraviroc. Conclusiones y perspectivas [Conclusions and perspectives. Maraviroc]. Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:49-54. Review. Spanish.
  • Alcamí J. Ciclo replicativo del VIH. Dianas terapéuticas consolidadas y dianas potenciales [The HIV replication cycle. Established therapeutic targets and potential targets]. Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:3-10. Review. Spanish.
  • Alcamí P. HIV Persistence During Therapy--Third International Workshop. 4-7 December 2007, St Maarten, West Indies. IDrugs. 2008 Feb;11(2):87-9.
  • Bedoya LM, Alvarez A, Bermejo M, González N, Beltrán M, Sánchez-Palomino S, et al. Guatemalan plants extracts as virucides against HIV-1 infection. Phytomedicine. 2008 Jun;15(6-7):520-4.
  • Carratalà J, Alcamí J, Cordero E, Miró JM, Ramos JM. Investigación en enfermedades infecciosas [Infectious diseases research]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 15:40-50. Review. Spanish.
  • Coiras M, Camafeita E, López-Huertas MR, Calvo E, López JA, Alcamí J. Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics. 2008 Feb;8(4):852-73. Review.
  • Coiras M, López-Huertas MR, Mateos E, Alcamí J. Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IkappaBalpha and enhances HIV-1 replication in human T lymphocytes. Retrovirology. 2008 Dec 1;5:109.
  • Garcia-Perez J, Perez-Olmeda M, Sanchez-Palomino S, Perez-Romero P, Alcami J. A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Med. 2008 Mar;9(3):160-71.
  • Muñoz Sanz A, Pachón J; Grupo Promotor de la especialidad de Enfermedades Infecciosas en España. Manifiesto de Guadalupe: por el reconocimiento de la especialidad de enfermedades infecciosas en España [The Guadalupe Declaration: for the recognition of the Infectious Diseases specialty in Spain]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 15:65-6. Spanish.
  • Soriano V, Geretti AM, Perno CF, Fätkenheuer G, Pillay D, Reynes J, et al. Optimal use of maraviroc in clinical practice. AIDS. 2008 Nov 12;22(17):2231-40. Review.

 2007:

  • Arenzana-Seisdedos F, Alcami J. Inhibition de l’entrée du VIH par le blocage des corécepteurs : du concept au médicament. Virologie 2007;11:1-13.
  • Coiras M, López-Huertas MR, Rullas J, Mittelbrunn M, Alcamí J. Basal shuttle of NF-kappaB/I kappaB alpha in resting T lymphocytes regulates HIV-1 LTR dependent expression.Retrovirology. 2007 Aug 8;4:56.
  • Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.J Med Virol. 2007 Feb;79(2):127-37.
  • Ramírez de Arellano E, Martín C, Soriano V, Alcamí J, Holguín A. Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression.Virus Genes. 2007 Apr;34(2):111-6. Epub 2006 Dec 9.

2006:

  • Bedoya LM, del Olmo E, Sancho R, Barboza B, Beltrán M, García-Cadenas AE, et al. Anti-HIV activity of stilbene-related heterocyclic compounds. Bioorg Med Chem Lett. 2006 Aug 1;16(15):4075-9.
  • Coiras M, Camafeita E, Ureña T, López JA, Caballero F, Fernández B, et al. Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression. Proteomics. 2006 Apr;6 Suppl 1:S63-73.
  • Palao G, Santiago B, Galindo MA, Rullas JN, Alcamí J, Ramirez JC, et al. Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum. 2006 May;54(5):1473-81.
  • Ramírez de Arellano E, Soriano V, Alcamil J, Holguín A. New findings on transcription regulation across different HIV-1 subtypes. AIDS Rev. 2006 Jan-Mar;8(1):9-16. Review.

2005:

  • Alcami J, Bedoya LM. El estudio de la interacción virus-hospedador como fuente de nuevas dianas en la infección por el VIH. Enf Emerg 2005;7:58-66.
  • Alcamí J, Joseph Munné J, Muñoz-Fernández MA, Esteban M. Current situation in the development of a preventive HIV vaccine. Enferm Infecc Microbiol Clin. 2005 Jul;23 Suppl 2:5-24. Review. English, Spanish.
  • Bedoya LM, Beltrán M, Sancho R, Olmedo DA, Sánchez-Palomino S, del Olmo E, et al. 4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4447-50.
  • García F, Lejeune M, Climent N, Gil C, Alcamí J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis. 2005 May 15;191(10):1680-5.
  • García-Moruja C, Alonso-Lobo JM, Rueda P, Torres C, González N, Bermejo M, et al. Functional characterization of SDF-1 proximal promoter. J Mol Biol. 2005 Apr 22;348(1):43-62.
  • Joseph J, Etcheverry F, Alcami J, María GJ. A safe, effective and affordable HIV vaccine--an urgent global need. AIDS Rev. 2005 Jul-Sep;7(3):131-8. Review.
  • Joven B, González N, Aguilar F, Santiago B, Galindo M, Alcamí J, et al. Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. Arthritis Rheum. 2005 Jan;52(1):354-6.
  • Márquez N, Sancho R, Bedoya LM, Alcamí J, López-Pérez JL, Feliciano AS, et al. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antiviral Res. 2005 Jun;66(2-3):137-45.

 2004:

  • Alcamí J. Avances en la inmunopatología de la infección por el VIH [Advances in the immunopathology of HIV infection]. Enferm Infecc Microbiol Clin. 2004 Oct;22(8):486-96. Review. Spanish.
  • Alcamí J. Resumen del Área de Ciencia Básica de la 11th Conference on Retroviruses and Opportunistic Infections. HIV Conference Reports 2004;5:2-7.  
  • Alcami J. Lo Mejor en Investigación Básica. IF Inhibidores de Fusión Nº 2 2004.
  • Bermejo M, Sánchez-Palomino S, Usán L, Alcamí J. Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors. J Med Virol. 2004 Aug;73(4):502-7.
  • Climent N, Oliva H, García F, Gil C, Sánchez-Palomino S, Pumarola T, et al. Generación de anticuerpos monoclonales humanos a partir de individuos infectados por VIH [Generation of Human Monoclonal Antibodies from HIV-Infected Individuals]. Inmunología 2004;23(4):303-12.
  • García F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):823-30.
  • Gil J, Bermejo M, Alcamí J. HIV and apoptosis: a complex interaction between cell death and virus survival. Prog Mol Subcell Biol. 2004;36:117-49. Review.
  • Gil J, García MA, Gomez-Puertas P, Guerra S, Rullas J, Nakano H, et al. TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol. 2004 May;24(10):4502-12.
  • Rullas J, Bermejo M, García-Pérez J, Beltán M, González N, Hezareh M, et al. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther. 2004 Aug;9(4):545-54.
  • Sancho R, Márquez N, Gómez-Gonzalo M, Calzado MA, Bettoni G, Coiras MT, et al. Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway.  J Biol Chem. 2004 Sep 3;279(36):37349-59.
  • Sancho R, Medarde M, Sánchez-Palomino S, Madrigal BM, Alcamí J, Muñoz E, et al. Anti-HIV activity of some synthetic lignanolides and intermediates. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4483-6.

 2003:

  • Alcamí J. Luces y Sombras de 20 años de Investigación en SIDA. Ars Médica. Revista de Humanidades 2003;2:250-259 .
  • Amara A, Vidy A, Boulla G, Mollier K, Garcia-Perez J, Alcamí J, et al. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates.J Virol. 2003 Feb;77(4):2550-8.

2002:

  • Alcami,J. Resumen área de ciencia básica XIV Conferencia Internacional sobre el SIDA. Enf.Emerg.2002;4:30-35.     
  • Alcami J. Situación actual en el desarrollo de una vacuna frente al virus de la inmunodeficiencia humana  [Present situation regarding development of an HIV vaccine]. Enferm Infecc Microbiol Clin. 2002 Dec;20(10):511-22. Review. Spanish.
  • Alcami,J. Aspectos de ciencia básica de la XIV Conferencia Internacional sobre SIDA. HIV Conference Reports 3/2002.
  • Alcami J. Summary on Track A – Basic Science. XIV International AIDS Conference. Newsletter IAS nº 22. 2002               
  • Arrizabalaga J, Alcamí J, Dalmau D, Delgado R, Miró J, Soriano V. Herramientas de laboratorio para individualizar el tratamiento: resistencias y niveles de fármacos [Laboratory tools for personalising treatment: resistance and drug levels]. Enferm Infecc Microbiol Clin. 2002 Jul;20(Supl 2):35-47. Spanish.
  • Bedoya LM, Palomino SS, Abad MJ, Bermejo P, Alcami J. Screening of selected plant extracts for in vitro inhibitory activity on human immunodeficiency virus. Phytother Res. 2002 Sep;16(6):550-4.
  • Berenguer J, González J, Pulido F, Padilla B, Casado JL, Rubio R, Arribas JR; Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin Infect Dis. 2002 Feb 1;34(3):394-7.
  • De Mendoza C, Alcamí J, Sainz M, Folgueira D, Soriano V. Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma. J Clin Microbiol. 2002 Apr;40(4):1518-21.
  • Sanchez Palomino S, Abad MJ, Bedoya LM, García J, Gonzales E, Chiriboga X, et al. Screening of South American plants against human immunodeficiency virus: preliminary fractionation of aqueous extract from Baccharis trinervis. Biol Pharm Bull. 2002 Sep;25(9):1147-50.
  • Soriano A, Martínez C, García F, Plana M, Palou E, Lejeune M, et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis. 2002 Oct 1;186(7):922-31.

2001:

  • Alcamí J, Delgado R, Menéndez-Arias L. Bases biológicas de la generación de resistencias a fármacos antirretrovirales [Biological basis for generating resistance to antiretroviral drugs]. Enferm Infecc Microbiol Clin. 2001 Feb;19(Monografico):3-13. Review. Spanish.
  • Alcamí J, Rubio R. Pruebas de resistencias a antiretrovirales, un elemento necesario en el seguimiento del paciente con infección por VIH. [Antiretroviral resistance testing. A necessary element in the follow-up of the HIV-infected patient]. Enferm Infecc Microbiol Clin. 2001 Feb;19(Monografico):1-2. Spanish.
  • Alcami J, Rullas J, Bermejo M, Beltrán M, Sánchez-Palomino,S. Inmunopatología del Sida. Medicina Integral: Monográfico/Sida en el siglo XXI. 2001;37:10.
  • Bedoya LM, Sanchez-Palomino S, Abad MJ, Bermejo P, Alcami J. Anti-HIV activity of medicinal plant extracts. J Ethnopharmacol. 2001 Sep;77(1):113-6.
  • Galindo M, Santiago B, Alcami J, Rivero M, Martín-Serrano J, Pablos JL. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol. 2001 Jan;123(1):36-41.
  • Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum. 2001 Jun;44(6):1382-6.
  • Gatell JM, Blanco JL, Alcamí J, Antela A, Arrizabalaga J, Casado JL, et al. Documento de consenso de GESIDA sobre la utilización de los estudios de resistencias en la práctica clínica [GESIDA Consensus document on the use of resistance studies in clinical practice]. Enferm Infecc Microbiol Clin. 2001 Feb;19(Monografico):53-60. Review. Spanish.
  • Gil J, Rullas J, Alcamí J, Esteban M. MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF-kappaB activation and apoptosis induced by PKR. J Gen Virol. 2001 Dec;82(Pt 12):3027-34.
  • Gil J, Rullas J, García MA, Alcamí J, Esteban M. The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation. Oncogene. 2001 Jan 18;20(3):385-94.
  • Gómez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem. 2001 Sep 21;276(38):35435-43.
  • Iglesias-De La Cruz MC, Ruiz-Torres P, Alcamí J, Díez-Marqués L, Ortega-Velázquez R, Chen S, et al. Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int. 2001 Jan;59(1):87-95.
  • Jiménez JL, Sánchez-Ramón S, Palomino SS, Alcamí J, Muñoz-Fernández HA. Where does free infective HIV-1 rebound come from? AIDS. 2001 Mar 30;15(5):657.

2000:

  • Gil J, Alcamí J, Esteban M. Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene. 2000 Mar 9;19(11):1369-78.
  • Mañes S, del Real G, Lacalle RA, Lucas P, Gómez-Moutón C, Sánchez-Palomino S, et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 2000 Aug;1(2):190-6.

1999:

  • Gil J, Alcamí J, Esteban M. Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol. 1999 Jul;19(7):4653-63.
  • Laín de Lera T, Folgueira L, Martín AG, Dargemont C, Pedraza MA, Bermejo M, et al. Expression of IkappaBalpha in the nucleus of human peripheral blood T lymphocytes. Oncogene. 1999 Feb 25;18(8):1581-8.
  • Ledesma E, Soriano V; HIV Drug Resistance Spanish Panel. Spanish consensus conference on drug resistance testing in clinical practice. HIV drug resistance Spanish panel. AIDS. 1999 Oct 1;13(14):1998-2001. Review.
  • Llorente M, Sánchez-Palomino S, Mañes S, Lucas P, Kremer L, De Alborán IM, et al. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Scand J Immunol. 1999 Sep;50(3):270-9.
  • Mas A, Español T, Heredia A, Pedraza MA, Hernandez M, Caragol I, et al. CCR5 genotype and HIV-1 infection in perinatally-exposed infants. J Infect. 1999 Jan;38(1):9-11.
  • Pedraza MA, del Romero J, Roldán F, García S, Ayerbe MC, Noriega AR, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):120-5.

1998:

  • Bermejo M, Martín-Serrano J, Oberlin E, Pedraza MA, Serrano A, Santiago B, et al. Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. Eur J Immunol. 1998 Oct;28(10):3192-204.
  • Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998 Apr 17;426(2):271-8.
  • Martín-Serrano J, Folgueira L, Laín de Lera T, Pedraza MA, Lemichez E, Sánchez-Palomino S, et al. In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4. AIDS. 1998 May 28;12(8):859-63.
  • Quiñones-Mateu ME, Mas A, Lain de Lera T, Soriano V, Alcamí J, Lederman MM, et al. LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Res. 1998 Sep;57(1):11-20.

1997:

  • Frade JM, Llorente M, Mellado M, Alcamí J, Gutiérrez-Ramos JC, Zaballos A, et al. The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection.J Clin Invest. 1997 Aug 1;100(3):497-502.
  • González CI, Thomas MC, Martín F, Alcami J, Alonso C, López MC. Reverse transcriptase-like activity in Trypanosoma cruzi. Acta Trop. 1997 Feb;63(2-3):117-26.

1995:

  • Alcamí J, Laín de Lera T, Folgueira L, Pedraza MA, Jacqué JM, Bachelerie F, et al. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J. 1995 Apr 3;14(7):1552-60.
  • Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Gil A, García de Lomas J, Delgado R, Borleffs JCC, Hsu A, Valdés JM, Boucher CAB, Cooper DA; European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995 Dec 7;333(23):1528-33.

1994:

  • Michelson S, Alcami J, Kim SJ, Danielpour D, Bachelerie F, Picard L, et al. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1.J Virol. 1994 Sep;68(9):5730-7.

1993:

  • Alcami J, Paya CV, Virelizier JL, Michelson S. Antagonistic modulation of human cytomegalovirus replication by transforming growth factor beta and basic fibroblastic growth factor. J Gen Virol. 1993 Feb;74 ( Pt 2):269-74.
  • Diaz-Meco MT, Berra E, Municio MM, Sanz L, Lozano J, Dominguez I, et al. A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol. 1993 Aug;13(8):4770-5.

1992:

  • Aullo P, Alcami J, Popoff MR, Klatzmann DR, Murphy JR, Boquet P. A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J. 1992 Feb;11(2):575-83.
  • Paya CV, Ten RM, Bessia C, Alcami J, Hay RT, Virelizier JL. NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7826-30.
  • Rivera-Guzmán JM, Regueiro JR, Alcamí J, Arnaiz-Villena A. CD11b-bearing mononuclear leucocytes and IgA levels in the staging of human immunodeficiency virus infection. Experientia. 1992 Apr 15;48(4):402-4.

1991:

  • Alcami J, Barzu T, Michelson S. Induction of an endothelial cell growth factor by human cytomegalovirus infection of fibroblasts.J Gen Virol. 1991 Nov;72 ( Pt 11):2765-70.
  • Bachelerie F, Alcami J, Arenzana-Seisdedos F, Virelizier JL. HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes.Nature. 1991 Apr 25;350(6320):709-12.

1990:

  • Bachelerie F, Alcami J, Hazan U, Israël N, Goud B, Arenzana-Seisdedos F, et al. Constitutive expression of human immunodeficiency virus (HIV) nef protein in human astrocytes does not influence basal or induced HIV long terminal repeat activity. J Virol. 1990 Jun;64(6):3059-62.
  • Hazan U, Thomas D, Alcami J, Bachelerie F, Israel N, Yssel H, et al. Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription. Proc Natl Acad Sci U S A. 1990 Oct;87(20):7861-5.

1989:

  • Arenzana-Seisdedos F, Israël N, Bachelerie F, Hazan U, Alcami J, Dautry F, et al. c-Ha-ras transfection induces human immunodeficiency virus (HIV) transcription through the HIV-enhancer in human fibroblasts and astrocytes. Oncogene. 1989 Nov;4(11):1359-62.
  • Israël N, Hazan U, Alcami J, Munier A, Arenzana-Seisdedos F, Bachelerie F, et al. Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. J Immunol. 1989 Dec 15;143(12):3956-60.

1988:

  • Alcami Pertejo J, Lizasoain Hernández M, Martínez Fernández R, Rubio García R, Mesa Latorre J, Medina Asensio J, et al. ¿Es aplicable la clasificación Walter Reed para el estadiaje de la infección HIV en pacientes heroinómanos?[Is the Walter Reed classification applicable for the staging of HIV infection in heroin-addicted patients?]. Rev Clin Esp. 1988 Apr;182(6):311-3. Spanish.

 

Go to top

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site